Pharma

Your Article Summary

See Latest Articles

Merck and Schering-Plough Resolve Previously Disclosed Civil Class Action Lawsuits Related to VYTORIN (ezetimibe/simvastatin) and ZETIA (ezetimibe)
Merck & Co., 08/06/09

Merck and Co., Inc., Schering–Plough Corporation and the companies' cholesterol joint venture, Merck/Schering–Plough Pharmaceuticals, announced that they have entered into agreements to resolve, for a total fixed amount of $41.5 million, civil class action litigation currently pending against the companies relating to the purchase or use of VYTORIN and ZETIA. The MSP joint venture recorded these charges in the second quarter 2009.

Today in M&A/Partnerships...keeping you current

Receive free subspecialty "5-minute updates" via email

Array BioPharma and Amgen Partner in Type 2 Diabetes
Amgen, 12/15/09

Inno Biologics and CEVEC Sign License Agreement for Human CAP Technology
b3c newswire, 12/09/09

Federal Advisory Committees to Meet
HealthDataManagement, 12/09/09

 See all of M&A/Partnerships